

WHO - DRAFT landscape of COVID-19 candidate vaccines – 10 August 2020

	COVID-19 Vaccine developer/manufacturer	Vaccine platform	Type of candidate vaccine	Number of doses	Timing of doses	Route of Administration	Clinical Stage			
							Phase 1	Phase 1/2	Phase 2	Phase 3
1	University of Oxford/AstraZeneca	Non-Replicating Viral Vector	ChAdOx1-S	1		IM		PACTR202006922165132 2020-001072-15 Interim Report	2020-001228-32	ISRCTN89951424
2	Sinovac	Inactivated	Inactivated	2	0, 14 days	IM		NCT04383574 NCT04352608		NCT04456595
3	Wuhan Institute of Biological Products/Sinopharm	Inactivated	Inactivated	2	0,14 or 0,21 days	IM		ChiCTR2000031809		ChiCTR2000034780
3	Beijing Institute of Biological Products/Sinopharm	Inactivated	Inactivated	2	0,14 or 0,21 days	IM		ChiCTR2000032459		
4	Moderna/NIAID	RNA	LNP-encapsulated mRNA	2	0, 28 days	IM	NCT04283461 Interim Report		NCT04405076	NCT04470427
5	BioNTech/Fosun Pharma/Pfizer	RNA	3 LNP-mRNAs	2	0, 28 days	IM		2020-001038-36 ChiCTR2000034825		NCT04368728
6	CanSino Biological Inc./Beijing Institute of Biotechnology	Non-Replicating Viral Vector	Adenovirus Type 5 Vector	1		IM	ChiCTR2000030906 Study Report		ChiCTR2000031781 Study Report	
7	Inovio Pharmaceuticals/International Vaccine Institute	DNA	DNA plasmid vac. with electropor.	2	0, 28 days	ID		NCT04447781 NCT04336410		